Q-omics provides the consensus-scored TNFAIP8L2 profile across patient tissues and cancer cell-line models. TNFAIP8L2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TNFAIP8L2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TNFAIP8L2 protein abundance shows 24,636 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where TNFAIP8L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFAIP8L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFAIP8L2 survival associations across molecular data types. TNFAIP8L2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFAIP8L2 RNA expression–survival associations across cancer types. High TNFAIP8L2 expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, SKCM, CESC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TNFAIP8L2 RNA expression.
This table summarizes TNFAIP8L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TNFAIP8L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFAIP8L2 shows lower tumor expression in COAD, LUSC and LUAD and higher tumor expression in KIRC, THCA and KIRP. The KIRC box plot shows higher TNFAIP8L2 RNA expression in tumor versus normal tissue (log2 FC = +2.262, t-test p < 0.001).
This table shows molecular features associated with TNFAIP8L2 in patient tissues and cancer cell lines. In patient samples, TNFAIP8L2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFAIP8L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
